225 related articles for article (PubMed ID: 25922594)
1. Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells.
Kim JS; Kim YG; Pyo M; Lee HK; Hong JT; Kim Y; Han SB
Immune Netw; 2015 Apr; 15(2):58-65. PubMed ID: 25922594
[TBL] [Abstract][Full Text] [Related]
2. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
4. Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features.
Gammaitoni L; Giraudo L; Leuci V; Todorovic M; Mesiano G; Picciotto F; Pisacane A; Zaccagna A; Volpe MG; Gallo S; Caravelli D; Giacone E; Venesio T; Balsamo A; Pignochino Y; Grignani G; Carnevale-Schianca F; Aglietta M; Sangiolo D
Clin Cancer Res; 2013 Aug; 19(16):4347-58. PubMed ID: 23794732
[TBL] [Abstract][Full Text] [Related]
5. Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma.
Li H; Huang L; Liu L; Wang X; Zhang Z; Yue D; He W; Fu K; Guo X; Huang J; Zhao X; Zhu Y; Wang L; Dong W; Yan Y; Xu L; Gao M; Yang S; Zhang Y
Cancer Immunol Immunother; 2017 Mar; 66(3):299-308. PubMed ID: 27889798
[TBL] [Abstract][Full Text] [Related]
6. Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.
Gammaitoni L; Giraudo L; Macagno M; Leuci V; Mesiano G; Rotolo R; Sassi F; Sanlorenzo M; Zaccagna A; Pisacane A; Senetta R; Cangemi M; Cattaneo G; Martin V; Coha V; Gallo S; Pignochino Y; Sapino A; Grignani G; Carnevale-Schianca F; Aglietta M; Sangiolo D
Clin Cancer Res; 2017 May; 23(9):2277-2288. PubMed ID: 27815354
[No Abstract] [Full Text] [Related]
7. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
8. Autologous cytokine-induced killer cell immunotherapy may improve overall survival in advanced malignant melanoma patients.
Zhang Y; Zhu Y; Zhao E; He X; Zhao L; Wang Z; Fu X; Qi Y; Ma B; Song Y; Gao Q
Immunotherapy; 2017 Nov; 9(14):1165-1174. PubMed ID: 29067881
[TBL] [Abstract][Full Text] [Related]
9. Increased survival time of a patient with metastatic malignant melanoma following immunotherapy: A case report and literature review.
Zhang Y; Song Y; Gao Q
Oncol Lett; 2015 Aug; 10(2):883-886. PubMed ID: 26622588
[TBL] [Abstract][Full Text] [Related]
10. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
11. Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models.
Iaia I; Gammaitoni L; Cattaneo G; Giraudo L; Donini C; Fiorino E; Primo L; Carnevale-Schianca F; Aglietta M; Puliafito A; Sangiolo D
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065007
[TBL] [Abstract][Full Text] [Related]
12. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
13. Combination of FAK inhibitor and cytokine-induced killer cell therapy: An alternative therapeutic strategy for patients with triple-negative breast cancer.
Wu CC; Pan MR; Shih SL; Shiau JP; Wu CC; Chang SJ; Kao CN; Chen FM; Hou MF; Luo CW
Biomed Pharmacother; 2023 Jul; 163():114732. PubMed ID: 37254289
[TBL] [Abstract][Full Text] [Related]
14. Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells.
Kim JS; Kim YG; Park EJ; Kim B; Lee HK; Hong JT; Kim Y; Han SB
Immune Netw; 2016 Apr; 16(2):99-108. PubMed ID: 27162526
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
Tao L; Huang G; Shi S; Chen L
Med Oncol; 2014 Jan; 31(1):777. PubMed ID: 24271420
[TBL] [Abstract][Full Text] [Related]
16. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy.
Helms MW; Prescher JA; Cao YA; Schaffert S; Contag CH
Cancer Immunol Immunother; 2010 Sep; 59(9):1325-34. PubMed ID: 20532883
[TBL] [Abstract][Full Text] [Related]
17. Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition.
Elia AR; Circosta P; Sangiolo D; Bonini C; Gammaitoni L; Mastaglio S; Genovese P; Geuna M; Avolio F; Inghirami G; Tarella C; Cignetti A
Hum Gene Ther; 2015 Apr; 26(4):220-31. PubMed ID: 25758764
[TBL] [Abstract][Full Text] [Related]
18. MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer.
Wang Z; Liu Y; Zhang Y; Shang Y; Gao Q
Oncotarget; 2016 Jan; 7(4):4760-9. PubMed ID: 26716894
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer.
Chen J; Chen Y; Feng F; Chen C; Zeng H; Wen S; Xu X; He J; Li J
J Thorac Dis; 2018 Dec; 10(12):6711-6721. PubMed ID: 30746216
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
